From clinical trials to routine practice: 7-year results of the monarchE randomized clinical trial and experience with the use of abemaciclib in hormone-dependent, HER2-negative, high-risk, early breast cancer

The 7-year results of the monarchE randomized clinical trial of adjuvant endocrine therapy escalation with abemaciclib in patients with hormone-dependent, HER2-negative, high-risk, early breast cancer. Three-year experience with the use of abemaciclib in 64 patients with hormone-dependent, HER2-negative, early breast cancer in real-world practice is analyzed, and the criteria for selecting combination endocrine therapy and the safety profile of treatment escalation are assessed. An indirect comparison of data from the Russian analysis and the randomized clinical monarchE trial of adjuvant endocrine therapy escalation in patients with a high risk of recurrence is conducted. Clinical cases of abemaciclib use in routine practice in Russian patients are presented.